Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes

Br J Haematol. 2018 Feb;180(4):603-604. doi: 10.1111/bjh.14417. Epub 2016 Oct 21.
No abstract available

Keywords: acute leukaemia; leukaemia; pregnancy.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Azacitidine / administration & dosage
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / drug therapy*
  • Molecular Targeted Therapy
  • Niacinamide / administration & dosage
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds / administration & dosage
  • Pregnancy
  • Pregnancy Complications, Neoplastic / diagnosis
  • Pregnancy Complications, Neoplastic / drug therapy*
  • Sorafenib
  • Treatment Outcome

Substances

  • Phenylurea Compounds
  • Niacinamide
  • Sorafenib
  • Azacitidine